fluoxymesterone
Approved
Oct 15, 1956
Fluoxymesterone, sold under the brand names Halotestin and Ultandren among others, is a synthetic, orally active androgenic-anabolic steroid (AAS) and a 17α-alkylated derivative of testosterone developed by Pharmacia & Upjohn Company LLC, approved by FDA at 1956. Fluoxymesterone is used in the treatment of hypogonadism in males and breast cancer in women. Fluoxymesterone has a relatively high ratio of androgenic to anabolic activity similarly to testosterone. Like many 17α-alkylated AAS, it has a relatively low affinity for the androgen receptor (AR). However, its actions are mediated by the AR, most likely due to its relatively long elimination half-life of approximately 9.2 hours. — NCATS
Clinical trial activity
1 trials · 2 clinical orgs · 6 marketing orgs
Earliest trial started Jun 1, 2005 (NCT00303615)
Timeline
1950s
- Oct 15, 1956
Earliest FDA Approval
- Oct 15, 1956
Pharmacia & Upjohn — NDA Secondary Org
1980s
- Jul 6, 1981
Bausch Health Companies — Marketing Organization
- Oct 21, 1983
Upsher-Smith Laboratories — Marketing Organization
2000s
- Jan 1, 2005
Earliest Phase 2 Sponsor(trial)
Indications
Approved for
Studied for
Mechanism of action
- Androgen ReceptorAGONIST
AR agonist
Approval history
- approvedPriority reviewOct 15, 1956
Chemistry & pharmacology
SMILES
C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C- Mol. weight
- 336.4409 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Delivery
- Oral
- Availability
- Discontinued
Oral
Yes
Parenteral
No
Topical
No
Sources
- WikipediaFluoxymesterone ↗
- NCATS9JU12S4YFY ↗
- ChEMBLCHEMBL1445 ↗
Also known as
- 11beta,17beta-dihydroxy-9alpha-fluoro-17alpha-methyl-4-androster-3-one
- 11beta,17beta-dihydroxy-9alpha-fluoro-17alpha-methyl-4-androster-3-one
- 17alpha-methyl-9alpha-fluoro-11beta-hydroxytesterone
- 17alpha-methyl-9alpha-fluoro-11beta-hydroxytesterone
- 17α-methyl-9α-fluoro-11β-hydroxytesterone
- 17α-methyl-9α-fluoro-11β-hydroxytesterone
- 9alpha-fluoro-11beta-hydroxy-17-methyltestosterone
- 9alpha-fluoro-11beta-hydroxy-17-methyltestosterone
- 9-fluoro-11beta,17beta-dihydroxy-17-methylandrost-4-en-3-one
- 9-fluoro-11beta,17beta-dihydroxy-17-methylandrost-4-en-3-one
- androfluorene
- androfluorone
- android-f
- android-f
- androxy
- androxy
- fluotestin
- fluoximesterona
- fluoximesterona
- fluoximesterone
- fluoximesterone
- fluoximesterone
- fluoxymesterone
- fluoxymesterone
- fluoxymesterone
- fluoxymesterone
- fluoxymesterone
- fluoxymesterone
- fluoxymesterone
- fluoxymesterone
- fluoxymesterone
- fluoxymesterone
- fluoxymesterone
- fluoxymesteronum
- fluoxymesteronum
- halotestin
- halotestin
- halotestin
- ora-testryl
- ora-testryl
- testosterone, 9-fluoro-11beta-hydroxy-17-methyl-
- testosterone, 9-fluoro-11beta-hydroxy-17-methyl-
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00303615 | Phase 2 | Jun 1, 2005 | Good Samaritan Foundation, Legacy Health System |
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Good Samaritan Foundation | Academic/Hospital | 1 | 0 | 1 | 2005 |
| Legacy Health System | Academic/Hospital | 1 | 1 | 1 | 2005 |
Marketing (7)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| Bausch Health Companies | For profit | MKTG | Jul 6, 1981 |
| Bristol-Myers Squibb | For profit | NDA2 | — |
| Pharmacia & Upjohn | For profit | NDA2 | Oct 15, 1956 |
| Upjohn | For profit | NDA | — |
| Upsher-Smith Laboratories | For profit | MKTG | Oct 21, 1983 |
| Upsher-Smith Laboratories | For profit | SYN | Oct 21, 1983 |
| Watson Pharmaceuticals | For profit | MKTG | — |